IMR Press / EJGO / Volume 38 / Issue 1 / DOI: 10.12892/ejgo3880.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Editorial Article
Combination therapy of cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) and programmed death 1 (pd1) blocker, check point inhibitors for treatment of patients with advanced and recurrent epithelial ovarian cancer
Show Less
1 The Joan and Sanford I. Weill Medical College, and The New York Presbyterian Hospital/ Weill Cornell Medical Center, Cornell University, New York, NY, USA
Eur. J. Gynaecol. Oncol. 2017, 38(1), 7–9;
Published: 10 February 2017

The standard of care for patients with recurrent ovarian cancer is platinum-based combination chemotherapy for those who relapse more than six months after completing adjuvant therapy. The use of biological agents such as bevacizumab has increased progressionfree survival (PFS), but has not shown a significant increase in overall survival (OS). Immunotherapy treatment modality is being actively pursued for patients with ovarian cancer. The goal of immunotherapy is to generate a tumor specific, T cell response that decrease residual disease, and protects against future recurrence. Combination therapy of anti-PD-1 antibodies, and anti-CTLA-4 antibodies reverses the TIL dysfunction and induces tumor regression in solid tumors, including ovarian cancer. When GM-CSF vaccine is added, it results in increased tumor rejection.
Recurrent epithelial ovarian cancer
Ovarian cancer immunotherapy
GM-CSF gene vaccine
Anti-PD1 antibodies
anti CTLA-4 antibodies
Back to top